Shots:
- Bracco Imaging has received the US FDA 510(k) clearance & Health Canada authorization for VueJect, its dedicated ultrasound contrast delivery system designed specifically for cardiology imaging
- VueJect is designed to improve workflow efficiency, reduce operator variability & enable continuous administration of ultrasound contrast agents for more consistent enhancement during cardiac imaging
- VueJect will initially launch in the US & Canada, with additional regulatory submissions planned in other markets. The system expands Bracco’s contrast-enhanced ultrasound ecosystem & strengthens its portfolio of integrated diagnostic imaging solutions
Ref: PRnewswire | Image: Bracco Imaging | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
